AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06758037
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W
Trial: NCT06765603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06776432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06776432
Drug: SASS-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT06777485
Drug: Anti-Tumor Drugs
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Trial: NCT06274294
Drug: CT-P13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment.
Trial: NCT04981717
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC for a total of 5 administrations
Trial: NCT04686955
Drug: Xiao-Xian-Gui-Fu-Tang
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
Trial: NCT06306300
Drug: Non- specialist - Epclusa 400Mg-100Mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
Trial: NCT05309811
Drug: Routine IOP-lowering medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications prescribed for IOP control by glaucoma specialists in the outpatient.
Trial: NCT05504278
Drug: IBI351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recommended dose, po
Trial: NCT06775314
Drug: Combination cream
RxNorm normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic acid will be given to subjects to be applied every morning, evening and night in group 2
Trial: NCT06775314
Drug: spot cream
RxNorm normalized name: Cold Spot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2
Trial: NCT06775314
Drug: placebo cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cleanser will be given to subjects to be applied every morning, evening and night in group 1
Trial: NCT06775314
Drug: placebo cream combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1
Trial: NCT06775314
Drug: placebo spot cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo spot cream will be given to subjects to be applied every morning and evening in group 1
Trial: NCT06775522
Drug: YHP2205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: YHP2205 Comparator: YHR2401
Trial: NCT06775522
Drug: YHR2401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: YHP2205 Comparator: YHR2401
Trial: NCT05436418
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
Trial: NCT06771245
Drug: SYH9056 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO once daily
Trial: NCT06771427
Drug: Chinese herbal tea TBDESJS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
Trial: NCT06770933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
Trial: NCT06772454
Drug: Antitumor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles
Trial: NCT06778304
Drug: Gonal F
RxNorm normalized name: Gonal F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
Trial: NCT06778304
Drug: jzb30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
Trial: NCT05242744
Drug: [18F]FluorThanatrace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
Trial: NCT06778902
Drug: R-GemOx
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
Trial: NCT06760702
Drug: AUR109 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUR109 200mg (once daily)
Trial: NCT06760702
Drug: AUR109 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUR109 300mg once daily
Trial: NCT06766825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Trial: NCT05651594
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05651594
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06778603
Drug: a targeted probe B7H3-IRDye800CW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
Trial: NCT06739720
Drug: LingZhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
Trial: NCT06751394
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
Trial: NCT06739759
Drug: Modified Agonist protocol for IVF with additive treatments as HCQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: giving additive drugs to agonist protocolas HCQ
Trial: NCT06753864
Drug: Test (T)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
Trial: NCT05302986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
Trial: NCT05238233
Drug: Proparacaine Hydrochloride
RxNorm normalized name: Proparacaine Hydrochloride
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop will be given to participants
Trial: NCT06776861
Drug: PD-1 / PD-L1 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
Trial: NCT03586089
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of inactive placebo prepared in 250 ml D5W).
Trial: NCT06727552
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Administration
Trial: NCT06775093
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months
Trial: NCT06770881
Drug: JSKN033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
Trial: NCT06771050
Drug: Antibiotic Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines.
Trial: NCT06771050
Drug: Antibiotic Duration Part B - Two stage revision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability.
Trial: NCT06774963
Drug: LNCB74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
Trial: NCT06770426
Drug: carbogen with or without phenyleprhine
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Trial: NCT06771063
Drug: WXSH0102/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer WXSH0102 tablets/placebo orally.
Trial: NCT06775743
Drug: ORIENT-31 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus bevacizumab plus platinum-doublet chemotherapy
Trial: NCT05210192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
Trial: NCT05737082
Drug: HCP2201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 2 tablets once per period
Trial: NCT05737082
Drug: RLD2205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 2 tablets once per period
Trial: NCT05737082
Drug: RLD2206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet once per period
Trial: NCT06670950
Drug: SYT-510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation A fasted
Trial: NCT06670950
Drug: SYT-510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation B fasted
Trial: NCT06670950
Drug: SYT-510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation A fed
Trial: NCT06670950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation
Trial: NCT06750627
Drug: Multimodal Intravenous Analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)
Trial: NCT06769152
Drug: HLX43 DOSE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Trial: NCT06769152
Drug: HLX43 DOSE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Trial: NCT06769152
Drug: HLX43 DOSE 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Trial: NCT04948099
Drug: VIB1116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIB1116
Trial: NCT04948099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06780930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT06775431
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
RxNorm normalized name: Pethidine hydrochloride 50 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
Trial: NCT06775431
Drug: Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
Trial: NCT05619783
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 g phenylbutyrate and 1 g taurursodiol
Trial: NCT05673785
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion
Trial: NCT05673785
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion
Trial: NCT06334016
Drug: Cannabis sativa Extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vape THC
Trial: NCT06509191
Drug: Intervention 1
RxNorm normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5mg/day
Trial: NCT05169697
Drug: A:YH002+YH001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH002 on CnD1,YH001 on CnD8,Q3W
Trial: NCT05169697
Drug: B:YH002+YH001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH002 and YH001 on same day,Q3W
Trial: NCT05169697
Drug: YH002+YH001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional 3+3 dose escalation algorithm
Trial: NCT06495372
Drug: control group (standard of care + placebo).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care + placebo
Trial: NCT06773936
Drug: Induction Phase
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib, Dasatinib, Prednisone, and Methotrexate
Trial: NCT06773936
Drug: Re-Induction Phase
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
Trial: NCT06759064
Drug: zoledronic acid plus Sintilimab intraperitoneal injection
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
Trial: NCT05386121
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
Trial: NCT06744868
Drug: Placebo of THDBH120 injection (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single dose of placebo by subcutaneous injection.
Trial: NCT06744868
Drug: THDBH120 injection (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
Trial: NCT06744868
Drug: Placebo of THDBH120 injection (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo once weekly for four weeks by subcutaneous injection.
Trial: NCT06740552
Drug: Lipid Lowering Medication
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
Trial: NCT06784661
Drug: Lipid-Based Artificial Tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Trial: NCT06784661
Drug: Non-Lipid Artificial Tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
Trial: NCT05699408
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Trial: NCT06732622
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
Trial: NCT06731959
Drug: Flexlamose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexlamose solution via nebulizer for 28 days
Trial: NCT06731959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution via nebulizer for 28 days